C
Ciliatech has developed the Intercil® Uveal Spacer, a surgically implantable device that utilizes the supraciliary space to lower intraocular pressure in patients with primary open-angle and primary angle-closure glaucoma without entering the anterior chamber. This approach minimizes risks associated with traditional glaucoma surgeries, such as endothelial cell loss and the need for postoperative management, while maintaining future treatment options.
Updated 3 months ago
Funding
$5.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- Ciliatech has developed the Intercil® Uveal Spacer, a surgically implantable device that utilizes the supraciliary space to lower intraocular pressure in patients with primary open-angle and primary angle-closure glaucoma without entering the anterior chamber. This approach minimizes risks associated with traditional glaucoma surgeries, such as endothelial cell loss and the need for postoperative management, while maintaining future treatment options.